StockNews.AI
BIOA
StockNews.AI
180 days

Shareholders that lost money on BioAge Labs, Inc.(BIOA) should contact The Gross Law Firm about pending Class Action - BIOA

1. Shareholders urged to join a class action lawsuit against BioAge Labs. 2. BioAge halted its STRIDES Phase 2 trial for azelaprag citing liver safety concerns. 3. The stock dropped from $20.09 to $4.65 after the trial discontinuation news. 4. Registration for lead plaintiff claims is open until March 10, 2025.

4m saved
Insight
Article

FAQ

Why Bearish?

The halted trial and ensuing class action signal major safety and management concerns. Similar legal setbacks in biotech have historically led to steep price declines.

How important is it?

The lawsuit directly challenges core clinical claims and investor trust, significantly impacting price dynamics and market confidence.

Why Short Term?

The immediate legal proceedings and investor uncertainty drive a short-term impact, though long-term pipeline risks remain.

Related Companies

BIOA
NEW YORK, Feb. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioAge Labs, Inc. (NASDAQ: BIOA). Shareholders who purchased shares of BIOA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/bioage-labs-inc-loss-submission-form/?id=130521&from=4 CLASS PERIOD: This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to BioAge's registration statement for the initial public offering held on or about September 26, 2024. ALLEGATIONS: According to the complaint, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 trial for azelaprag, its lead product candidate, citing safety concerns over elevated liver transaminase levels in participants. This came as a surprise because, at the time of its IPO less than three months earlier, BioAge highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs.  Following this news, BioAge's stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024. DEADLINE: March 10, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/bioage-labs-inc-loss-submission-form/?id=130521&from=4 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of BIOA during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 10, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: [email protected]Phone: (646) 453-8903 SOURCE The Gross Law Firm

Related News